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ABSTRACT
Objective To compare the analgesic efficacy and side
effects of the synthetic cannabinoid nabilone with those
of the weak opioid dihydrocodeine for chronic
neuropathic pain.
Design Randomised, double blind, crossover trial of
14 weeks’ duration comparing dihydrocodeine and
nabilone.
Setting Outpatient units of three hospitals in the United
Kingdom.
Participants 96 patients with chronic neuropathic pain,
aged 23-84 years.
Main outcome measures The primary outcome was
difference between nabilone and dihydrocodeine in pain,
as measured by the mean visual analogue score
computed over the last 2 weeks of each treatment period.
Secondary outcomes were changes in mood, quality of
life, sleep, and psychometric function. Side effects were
measured by a questionnaire.
Intervention Patients received a maximum daily dose of
240 mg dihydrocodeine or 2 mg nabilone at the end of
each escalating treatment period of 6 weeks. Treatment
periods were separated by a 2 week washout period.
ResultsMean baseline visual analogue score was
69.6 mm (range 29.4-95.2) on a 0-100 mm scale. 73
patients were included in the available case analysis and
64 patients in the per protocol analysis. The mean score
was 6.0 mm longer for nabilone than for dihydrocodeine
(95%confidence interval 1.4 to 10.5) in the available case
analysis and 5.6 mm (10.3 to 0.8) in the per protocol
analysis. Side effects were more frequent with nabilone.
Conclusion Dihydrocodeine provided better pain relief
than the synthetic cannabinoid nabilone and had slightly
fewer side effects, although no major adverse events
occurred for either drug.
Trial registration Current Controlled Trials
ISRCTN15330757.
INTRODUCTION
The potential role of cannabinoid agents in the
management of neurological disease has attracted
considerable interest. Much of the evidence is
anecdotal and little sound clinical research is available.
Ameta-analysis examining cannabinoids failed to find
convincing evidence of analgesic activity beyond that
of weak opioids, although animal work continues to
suggest that cannabinoids may be useful for neuro-
pathic pain.1Apaperpublished after completionof this
trial showed some benefit in alleviating central pain in
patients with multiple sclerosis.2
Nabilone is a synthetic cannabinoid that is licensed in
the United Kingdom for the treatment of chemother-
apy induced nausea and vomiting. It is active against
cannabinoid receptors 1 and 2, and it is significantly
more potent than delta-9-tetrahydrocannabinol
(THC).3 Nabilone has a high bioavailability and
disappears from plasma in a biphasic manner. Its
rapid redistribution means it has a plasma half life of
two hours, and its total half life of only 20 hours implies
rapid metabolism and excretion. Clinical observation
indicates that its action is more prolonged, however,
possibly because of the presence of activemetabolites.4
Dihydrocodeine is a weak step II (World Health
Organization analgesic ladder) opioid, which is often
prescribed in primary care to treat chronic pain.5 Its
psychotropic and sedative side effects make it a good
comparative agent for a study with nabilone.6
Neuropathic pain is a common condition associated
with various injuries to the central and peripheral
nervous systems. It is often refractory to treatmentwith
currently available drugs, and other classes of “adju-
vant” drugs may be needed.7
Animal work has indicated a potential therapeutic
role for cannabinoids in neuropathic pain, and a study
of patients with refractory chronic pain conditions
showed benefit from treatment with nabilone.8 The
pain clinic in Newcastle started using nabilone on an
empirical basis in several chronic pain conditions in
1999 and found some evidence of efficacy.9 We
therefore performed a randomised crossover trial to
compare the analgesic efficacy of nabilone with that of
dihydrocodeine for neuropathic pain. We also com-
pared the side effects of both drugs.
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METHODS
Participants and setting
Our study took place between July 2001 and Novem-
ber 2002 in outpatient facilities of three hospitals in the
UnitedKingdom—theRoyalVictoria Infirmary,New-
castle upon Tyne; the Gartnavel General Hospital,
Glasgow; and the James Cook University Hospital,
Middlesbrough.
The trial protocol was shown to all clinicians who
worked in the chronic pain units of the participating
hospitals and clinicians who refer patients to the trial
centres were told about the trial. All suitable patients
(box)with neuropathic pain (such as burning, stabbing,
or paraesthesia within the distribution of a peripheral
nerve) and a clear clinical history of its cause were
referred by the participating pain consultants for
screening. One clinician (BF) screened, followed up,
and monitored all participants during the trial.
We screened 100 patients aged 24-84 years with
chronic neuropathic pain (see box for predefined
diagnostic criteria) for one to two weeks. To justify
treatment and enable improvements to be seen, the
patient’smeanpain score had to be greater than40mm
on a 0-100 mm visual analogue scale. Ninety six
patients were randomised to one of the two treatment
sequences. We allowed participants to keep taking
stable analgesics, except for dihydrocodeine, which
was stopped two weeks before the start of the study
drugs. All other analgesics were continued. We
excluded patients taking antipsychotics, benzodiaze-
pines (except for night sedation), and monoamine
oxidase inhibitors. Patients taking any cannabinoid
preparation at the time of screening were also
excluded, as were those with ongoing legal action
associated with their clinical condition. Patients with
severe hepatic or renal disease, epilepsy, bipolar
disorder, psychosis, or a history of substance misuse
were not included in the trial.
Procedures
After initial recruitment, patients supplied a daily pain
score for one week. During this week, a urine sample
was tested for cannabis and patients with a positive
sample were excluded. We took blood samples to
measure full blood count, electrolytes, urea, liver
function, and serum glucose. Urine was tested for
protein, blood, pH, and ketones using a dipstick.
Patients with abnormal values were not included in the
trial, except for those who had abnormal plasma
glucose and known insulin dependent diabetes.
Patients underwent an abbreviated neurological
examination, which included examining muscle
strength in both ankles and testing for ankle reflexes
(when appropriate), clinical allodynia, and hyperalge-
sia. Patients also had a general medical examination,
which concentrated on the skin, the respiratory system,
the cardiovascular system, and the gastrointestinal
system.
During the screening visit, patients filled in a hospital
anxiety and depression score (HAD score) and a short
form 36 quality of life questionnaire (SF-36—com-
monly used to measure health related quality of
life).10 11 All patients watched a demonstration of six
psychometric tests and practised the tests on the
computer until they were confident in the use of the
hardware.
Our study was a randomised, double blind, con-
trolled, crossover trial of three months’ duration. The
Table 1 | Timetable of visits and procedures
Timetable of observations
Study phase
Screening Drug A Washout Drug B
Study week -1 0 2 4 6 8 10 12 14
Visit Screening 1 2 3 4 5 6 7 8
Patient baseline data X
Inclusion and exclusion criteria X
Demographics X
Medical history X
Previouslyorcurrently takingdrugs X
Physical examination X X X X X X X X
Abbreviated neurological
examination
X
HAD score X X
SF-36 score X X
Psychometric testing X X X
Blood sampling X X
Urine sampling X
Side effect and adverse effect
assessment
X X X X X X X
Pain score recording X X X X X X X
Drug dispensing X X X X X X X
HAD=hospital anxiety and depression; SF-36=short form-36.
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three trial periods were—treatment period 1 (six
weeks), washout period (two weeks), and treatment
period 2 (six weeks). Participants made eight specified
visits at weeks 0, 2, 4, 6, 8, 10, 12, and 14 (table 1).
All patients were asked to fill in a diary recording the
average daily pain score, the number of hours slept,
details of interruptions to sleep (using a tick box), and
the amount of study drug taken. During the washout
phase the patients recorded the number of rescue
tablets (paracetamol 500 mg and codeine 30 mg per
tablet) taken each day.
At each visit the patients filled in a side effects
assessment form. During the fourth and eighth visits
they also filled in a HAD score and SF-36 form and
worked through the six psychometric tests.
Outcome measurements
Thepain scorewas the primary outcomevariable. Pain
scores are just one way to measure the benefit of
treatment in patients with chronic pain. Improvements
inmood, sleep, andquality of life are equally important
for most patients. Secondary outcomes were anxiety
and depression asmeasured by theHADscore, each of
the eight domains and the “change inhealth”measured
by the SF-36,12 and the weekly average number of
hours slept each night calculated from the diaries. We
calculated the scores for the psychometric tests from
the absolute results of each test divided by the time
taken to perform the test.
Weusedaneight itemquestionnaire that askedabout
the most common side effects of dihydrocodeine and
nabilone. Each question could be answered by circling
one of five discretional answers ranging from “Yes,
verymuch” to “Definitelynot.”Other sideeffects could
also be recorded. Only the answers “Yes, very much”
and “Yes,quite a lot”werecountedas sideeffects for the
analysis.
Study drugs
The trial drugs were given in an escalating manner
(fig 1). If the patient developed side effects, the dosage
was reduced to the previous value for the remainder of
the trial period after discussion with the investigator.
Patients were weaned off the drugs by halving the dose
every three days, and patients did not take any trial
drug for the last six days of thewashout periodbutwere
allowed up to eight tablets of rescue drugs a day.
The pharmacy at St Mary’s Hospital supplied
identical white capsules containing 250 µg nabilone
or 30 mg dihydrocodeine. The pharmacies at the
treatment centres, the patients, and all clinical person-
nel involved in the trial were unaware of treatment
allocation at all times.
Code breaking envelopes were kept in each hospital
pharmacy and each was used for only one patient. The
code was disclosed only to the requesting doctor who
was not involved in the study.
Statistical considerations
We randomised patients to receive nabilone first then
dihydrocodeine or vice versa. Treatmentwas allocated
by random permuted blocks of 10, stratified by centre.
Weusedamodelwith fixedpatient effect, period effect,
and treatment effect butno term for the carryover effect
of treatment to analyse the data.13 Normal errors were
assumed and this was checked using normal prob-
ability plots. Calculations of sample size were compli-
cated by the lack of information on within patient
variation for the visual analogue score. A study that
randomised 30 patients to each treatment sequence
would have 90% power to detect a difference in mean
visual analogue score between the treatments equal to
60% of the within patient standard deviation, at 5%
significance. This is broadly in line with previous
Baseline Double blind treatment
Randomisation
Dose of 
dihydrocodeine
Visits 
screening
Dose of 
dihydrocodeine
Dose of 
nabilone
Group 1
Group 2
Dose of 
nabilone
1 2 3 4 5 6 7 8
Weeks -1 0 2 4 6 8 10 12 14
30 mg 60 mg 120 mg 240 mg washout
1 mg 2 mg
1 mg 2 mg
washout
30 mg 60 mg 120 mg 240 mg
Fig 1 Study design
Inclusion and exclusion criteria
Diagnostic criteria
Sensory abnormality
Allodynia
Burning pain
Lancinating pain
Sympathetic dysfunction
Inclusion criteria
Presence of neuropathic pain according to the diagnostic
criteria
Patient taking a stable dose of analgesic
Age 18-90
Exclusion criteria
Epilepsy
Liver disease
Psychosis
Bipolar disorder
Substance misuse
Renal failure
Adverse events to dihydrocodeine or nabilone
Excluded drugs
Dihydrocodeine
Antipsychotics
Monoamine oxidase inhibitors
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studies.14 15 We anticipated that as many as 30% of
patients would drop out, so we aimed to recruit 100
patients.
Each treatment period lasted six weeks and we
collected data at the end of each period for all variables
except thepain score; this scorewas recordeddaily and
weekly means were analysed. The treatment periods
were separated by a washout period of two weeks. We
excluded carryover bybasing the analysis ondata from
the last twoweeks of each treatment period—weeks 5-6
andweeks 13-14. If data from one of the last twoweeks
were missing, we substituted data from the preceding
week (week 4 orweek 12). Because the use of data from
earlier weeks could produce bias from carryover
effects, if no data were available on a patient in the
last threeweeks of the period, the treatment periodwas
excluded. The use of a fixed patient effect in the
analysismeant that the patient was then excluded from
the analysis.
Two analyses are presented. The available case
analysis used the fullest dataset—all patients rando-
mised who provided data in each treatment period
(week 4 or beyond and week 12 or beyond). The per
protocol analysis excluded patients who did not
comply with the trial drugs, as assessed by their pain
diary.
Data were prepared used Minitab version 13 and
analyses were carried out with Stata version 7. We
recoded and tabulated the side effects using SPSS
version 11.
RESULTS
We screened 110 patients (fig 2). Ten were excluded
because of comorbidity or non-compliance with the
trial requirements. We screened 100 patients but
randomised only 96. Table 2 shows their demographic
profile and their clinical history with regard to
neuropathic pain and its treatment.
We allocated 48 patients to receive dihydrocodeine
and 48 to receive nabilone as first treatment. The
available case analysis included 73 patients, and 64
were retained for the per protocol analysis (fig 2). The
six non-compliant patients did not attend follow-up
appointments so only partial data from one study
period were available. We performed a detailed
breakdown of the data by each centre and by the
sequence of the treatment received. We found no
differences between centres or treatment sequences.
The mean baseline visual analogue score was
69.6 mm (range 29.4-95.2) on a 0-100 mm scale. The
mean (SD) visual analogue score was 59.93 (24.42) for
patients taking nabilone and 58.58 (24.08) for those
taking dihydrocodeine. The mean (SD) for nabilone
minus dihydrocodeinewas 1.59 (9.19) for patients who
took nabilone first then dihydrocodeine and −4.39
(10.32) for patients who took dihydrocodeine first then
nabilone.
Dihydrocodeine was a significantly better analgesic
than nabilone. The available case analysis produced a
treatment effect (in the direction nabilone minus
dihydrocodeine) of 6.0 mm (95% confidence interval
1.4 to 10.5, P=0.01). The equivalent figures for the per
protocol analysis were 5.6 mm (0.8 to 10.3, P=0.023).
If we assume that a drop in the visual analogue score
of more than 10 mm is a clinically relevant treatment
effect, threeof the64patients in theperprotocoldataset
had a clinically relevant response on nabilone com-
pared with 12 patients on dihydrocodeine. No patient
responded to both of the investigated drugs. Forty nine
patients had no clinically relevant drop in their pain
score on either treatment.
Table 3 gives details of the secondary outcomes. In
the available case analysis, the treatment effect for the
Patients referred from 
3 pain clinics (n=110)
Patients screened (n=100)
Patients excluded (n=10)
Patients randomised (n=96)
Available case analysis (n=73)
Per protocol analysis (n=64)
Patients received nabilone 
then dihydrocodeine (n=48)
Patients received dihydrocodeine 
then nabilone (n=48)
Patients supplied data
for the per protocol
analysis (n=34)
Patients supplied data
for the per protocol
analysis (n=30)
Patients suplied data
for the available case
analysis (n=39)
Patients suplied data
for the available case
analysis (n=34  )
Withdrawals:
Because of side effects on 
dihydrocodeine (n=6)
Because of side effects on nabilone (n=1)
Because of medical reasons (n=3)
Because of non-adherence (n=4)
Withdrawals: 
Because of side effects on 
dihydrocodeine (n=2)
Because of side effects on nabilone (n=3)
Because of medical reasons (n=3)
Because of personal reasons (n=1)
Because of non-adherence (n=2)
Patients did not supply sufficient
data because of increased pain 
on nabilone (n=3)
Patients did not supply sufficient
data because of constipation
on dihydrocodeine (n=1)
Patients did not adhere to trial drug (n=2)
Patients did not supply sufficient
data on dihydrocodeine 
due to side effects (n=3)
Trial medication packs expired (n=4)
Fig 2 Study flow chart
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Table 2 | Study population
Treatment group
Dihydrocodeine then nabilone Nabilone then dihydrocodeine
Patients (n) Mean (SD) Patients (n) Mean (SD)
Demographic details
Female 25 21
Male 23 27
Age (years) 48 50.6 (15.2) 48 49.7 (12.0)
Height (cm) 48 168.6 (9.6) 48 169.0 (11.5)
Weight (kg) 48 73.9 (15.4) 48 77.7 (18.3)
Duration of pain (months) 48 79.8 (67.9) 48 73.0 (70.3)
Baseline visual analogue score 47 68.0 (12.4) 48 66.4 (14.9)
Neuropathic pain syndrome
Cervical radiculopathy 0 1
Complex regional pain syndrome 5 4
Demyelination 4 7
Diabetic neuropathy 4 3
Guillain-Barré syndrome 0 1
Mononeuritis multiplex 1 0
Myelopathy 2 4
Neuropathy 1 0
Post-herpetic neuralgia 4 3
After injury or surgery 22 20
Spinal artery thrombosis 2 0
Spinal cord injury 1 0
Transverse myelitis 1 4
Trigeminal neuralgia 1 1
Previous treatment with non-steroidal anti-inflammatory drugs
No 16 9
Yes 32 39
Previous treatment with weak opioid
No 10 6
Yes 38 42
Previous treatment with antidepressant
No 5 7
Yes 43 41
Previous treatment with anticonvulsant
No 7 9
Yes 41 39
Previous treatment strong opioid
No 37 29
Yes 11 19
Signs of sensory abnormality
No 3 3
Yes 45 45
Signs of allodynia
No 22 15
Yes 26 33
Symptoms of burning pain
No 16 14
Yes 32 34
Symptoms of lancinating pain
No 5 7
Yes 43 41
Symptoms of sympathetic dysfunction
No 35 38
Yes 13 10
Origin of pain
Central 10 20
Peripheral 38 28
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SF-36 domain “role physical” was 8.9 (1.1 to 16.9,
P=0.03); these figureswere10.8 (2.3 to19.2,P=0.01) for
the per protocol analysis. In this domain, higher scores
indicate a better outcome, so these results show that
nabilone was significantly superior to dihydrocodeine
on this measure. In the available case analysis, the
treatment effect for the SF-36 domain bodily pain was
−5.2 (−10.1 to −0.4, P=0.03); these figures were −5.7
(−10.9 to −0.5, P=0.03) for the per protocol analysis.
Higher scores in the bodily pain domain indicate a
better outcome, so these results show that dihydroco-
deine was statistically superior to nabilone. These
results agree with those of the primary outcome
analysis.
Analysis of the psychometric testing found no
significant differences between the two drugs.
Table 4 provides details of the side effects. Nabilone
was associated with more sickness than dihydroco-
deine. Dihydrocodeine was associated with more
tiredness and nightmares than nabilone. No major
adverse events occurred when patients were taking
either drug and both drugs were equally well tolerated.
DISCUSSION
The weak opioid, dihydrocodeine, was a statistically
better treatment for chronic neuropathic pain than
nabilone. More patients had clinically significant pain
relief from dihydrocodeine, although a small number
of patients respondedwell to nabilone. The side effects
of both treatments were generally mild and in the
expected range.
Strengths and weaknesses
Our study had intrinsic sensitivity as it showed a
difference between the two treatments.
Weaker points of the study were that 33 patients
failed to complete the trial and the population studied
had a variety of neuropathic pain syndromes. The high
dropout rate can be explained partially by the cross-
over design—unlike a parallel group design this type of
trial exposes patients to two rather than one treatment.
In addition, the cannabinoid that we used was
synthetic and not plant based, so that the results are
not necessarily relevant to people who smoke mar-
ijuana preparations. However, the active constituents
of such preparations have been well characterised and
no compounds have been found to offer novel or
unpredicted actions at cannabinoid receptors.
Implications
The analgesic effects of opioids and cannabinoids are
mediated by separate mechanisms—the analgesic
effects of nabilone are not mediated by opioid
receptors.16 A recent study found that THC was not
Table 3 | Secondary outcomes for patientswith neuropathic pain treatedwith nabilone or dihydrocodeine
Outcome measured
Number of patients
analysed Treatment effect (95% confidence interval) P value
Available case analysis
Sleep 71 0.2 (−0.1 to 0.5) 0.20
Anxiety 70 −0.6 (−1.4 to 0.3) 0.19
Depression 70 −0.2 (−1.2 to 0.9) 0.72
Change in health 70 0.0 (−0.2 to 0.2) 0.88
Physical functioning 71 −1.2 (−4.5 to 2.1) 0.48
Social functioning 71 3.4 (−4.1 to 10.8) 0.37
Role, physical 69 8.9 (1.1 to 16.7) 0.03
Role, emotional 69 −1.2 (−11.8 to 9.5) 0.83
Mental health 71 2.5 (−2.7 to 7.6) 0.35
Vitality 71 −2.0 (−7.2 to 3.3) 0.46
Bodily pain 71 −5.2 (−10.1 to −0.4) 0.03
General health 70 0.8 (−3.1 to 4.6) 0.70
Per protocol analysis
Sleep 63 0.2 (−0.1 to 0.5) 0.28
Anxiety 62 −0.6 (−1.6 to 0.3) 0.18
Depression 62 −0.2 (−1.2 to 0.9) 0.78
Change in health 62 0.0 (−0.3 to 0.2) 0.76
Physical functioning 63 −1.4 (−5.1 to 2.4) 0.47
Social functioning 63 2.3 (−5.3 to 9.9) 0.54
Role, physical 62 10.8 (2.3 to 19.2) 0.01
Role, emotional 62 −0.6 (−11.4 to 10.2) 0.92
Mental health 63 2.0 (−3.2 to 7.1) 0.45
Vitality 63 −2.3 (−7.6 to 3.0) 0.39
Bodily pain 63 −5.7 (−10.9 to −0.5) 0.03
General health 63 0.5 (−3.7 to 4.7) 0.81
Positive values indicate higher scores with nabilone. Negative values indicate higher scores with dihydrocodeine.
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an effective analgesic when used alone but had a
pronounced synergistic effect when used with an
opioid.17 We found that the weak opioid, dihydroco-
deine, providedbetterpain relief than the cannabinoid,
nabilone, in the treatment of chronic neuropathic pain.
However, the clinical significance of this difference is
small, and neither drug was particularly effective.
Nabilone significantly improvedpatients’ scoreson the
“role physical” domain of the SF-36. Once again, the
clinical relevance of this improvement is relatively
small.
More patients taking dihydrocodeine had constipa-
tion, and surprisinglynabilonewasmore likely to cause
nausea even though it is used as an antiemetic.
Dihydrocodeine is a weak opioid with 10% of the
potency of oral morphine, so our maximum dose of
240 mg was equivalent to around 24 mg of oral
morphine.18 No data are available for the therapeutic
dosing of nabilone, and the dose of 2mgwas arrived at
as a compromise between safety and the effective dose
seen in our clinical practice.9 The observed side effect
profile argues against giving higher doses of nabilone.
Dihydrocodeine is a slightlymore effective analgesic
than codeine but less effective than tramadol and
morphine.19 20 This low potency opioid was more
effective than the potent cannabinoid, nabilone,
which argues against using this cannabinoid in clinical
practice and supports previous findings.21
Marijuana preparations act mainly through THC—
the most abundant and potent naturally occurring
cannabinoid. There has been some interest in
combining cannabidiol with THC as a way to reduce
some of the side effects of the active cannabinoid.
Although these actionsmaybe related to the antagonist
activity of cannabidiol, it has been suggested that
cannabidiol has intrinsic antipsychotic activity unre-
lated to its cannabinoid receptor effect. However, a
recent study found that including cannabidiol in THC
preparations had no advantages.22 Animal models
provide no evidence that cannabidiol has any form of
central analgesic activity and our findings—that the
intrinsic analgesic activity of nabilone in neuropathic
pain is at best modest—are relevant to the cannabinoid
debate.
Much has been made of the poor availability of oral
cannabinoids compared with inhaled agents. Recent
studies investigated an oromucosal spray of THC as a
way to deliver it to the central nervous system
rapidly.2 22 However, the rapid administration of
psychotropics has different effects from those seen
after slower administration. Cannabis—like many
other recreational drugs such as alcohol, ampheta-
mines, andopioids—actsonareasof thebrain related to
the “reward” pathways. Cannabinoid 1 receptors are
colocalised with opioid receptors on dopaminergic
cells of the nucleus accumbens, probably the most
important structure in the human reward system.23 The
reward system is triggered by rapidly rising drug
concentrations, so smoking, “snorting,” or injecting
certaindrugshas a greater effect on the systemthanoral
ingestion. For this reason, the results of studies using
rapid administration must be interpreted with caution.
Oral ingestion avoids high peak concentrations, and
considerations relating to bioavailability are less
relevant when drugs are used to treat chronic pain,
where fixed regular dosing is the norm.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Cannabinoids have been used as analgesics for centuries
but the evidence base for their use is poor
Psychotropicsideeffects limit therapeuticdosing inpatients
with chronic pain
Neuropathicpain isacommonanddifficult to treatcondition
that has limited treatment options
WHAT THIS STUDY ADDS
Nabilone, a synthetic oral cannabinoid, is notmore effective
for treating neuropathic pain than the oral opioid
dihydrocodeine
Table 4 | Side effects of nabilone or dihydrocodeine in patientswith neuropathic pain
Side effect Nabilone Dihydrocodeine
Tiredness 79 102
Sleeplessness 46 38
Sickness 46 10
Tingling 25 24
Strangeness 27 33
Nightmares 7 18
Shortness of breath 18 20
Headaches 20 19
Other 66 41
Total 334 305
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